Agonists of Toll-like receptors (TLRs) are potent activators of the innate immune system and hold promise as vaccine adjuvant and for anticancer immunotherapy. Unfortunately, in soluble form they readily enter systemic circulation and cause systemic inflammatory toxicity. Here we demonstrate that by covalent ligation of a smallmolecule imidazoquinoline-based TLR7/8 agonist to 50-nm-sized degradable polymeric nanogels the potency of the agonist to activate TLR7/8 in in vitro cultured dendritic cells is largely retained. Importantly, imidazoquinoline-ligated nanogels focused the in vivo immune activation on the draining lymph nodes while dramatically reducing systemic inflammation. Mechanistic studies revealed a prevalent passive diffusion of the nanogels to the draining lymph node. Moreover, immunization studies in mice have shown that relative to soluble TLR7/8 agonist, imidazoquinoline-ligated nanogels induce superior antibody and T-cell responses against a tuberculosis antigen. This approach opens possibilities to enhance the therapeutic benefit of small-molecule TLR agonist for a variety of applications.
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nanotechnology | Toll-like receptor | dendritic cells | lymph node | vaccine A ctivation of the innate immune system crucially depends on the recognition of evolutionary conserved microbe-associated molecular patterns by host pattern recognition receptors (PRRs). Triggering of PRRs not only elicits a direct antimicrobial and inflammatory cascade but also activates the necessary antigen-presenting cells to subsequently prime antigen-specific T-and B-cell immune responses (1) . Agonists of Toll-like receptors (TLRs) are among the most potent activators of the innate immune response identified to date and, thus, are under intensive investigation as adjuvants for vaccination (2) or as agents for anticancer immunotherapy (3) . Especially promising in this context are agonists of the endosomal TLR7 and TLR8, which typically recognize singlestranded RNAs generated during viral infection (4) but can also be activated by synthetic small-molecule agonists (5) . Molecular adjuvants (6, 7) that are agonists of TLR7/8 indeed activate a broad spectrum of antigen-presenting cells, both in mice (only TLR7) and humans, and typically induce high levels of type I IFN and IL-12, the most vital cytokines to drive the Th1 and cytotoxic T-cell responses required to combat intracellular infections and cancer (7, 8) .
Due to their pharmacokinetic profile, most molecular adjuvants rapidly diffuse after administration and evoke systemic inflammatory responses that cause dose-limiting toxicity (9, 10) . In the context of intratumoral administration, these dose-limiting toxicities prevent these compounds from reaching the necessary intratumoral concentration to yield real therapeutic benefit. In the context of vaccination, the rapid diffusion of molecular adjuvants dramatically lowers the ability of antigen and TLR agonist to reach the same antigen-presenting cells in the draining lymph node (DLN), which results in suboptimal immunity to the delivered vaccine antigen and by consequence wasted inflammation (11) . Coencapsulation of antigens and TLR agonists inside polymeric carriers through steric, hydrophobic, or electrostatic entrapment as a means to augment B-and T-cell immunity has been pursued by us and others (12) (13) (14) (15) (16) (17) (18) . Nevertheless, the procedures applied to entrap TLR agonists inside polymeric carriers are often highly complex and yield ill-defined systems that suffer from burst releases of the TLR agonist (19) following in vivo application. Covalent ligation of TLR agonists to polymeric nanoparticles might provide chemically better-defined alternatives to physical (co)encapsulation systems, as recently nicely highlighted by the Seder laboratory (20) .
Here, we report on the design of self-assembled, pH-degradable TLR7/8 agonist-ligated nanogels that efficiently restrict the innate immune-activating properties of the molecular adjuvant to the injection site and its DLN. Degradable polymer nanogels were prepared by self-assembly of amphiphilic block copolymers composed of a hydrophilic, PEG-like polymer block based on methoxy triethylene glycol methacrylate (mTEGMA) and a hydrophobic polymer block based on pentafluorophenyl methacrylate (PFPMA) (21) . The PEG-like hydrophilic block was used to provide nanoparticle stability and tissue mobility, as recently demonstrated by us and others (15, 22, 23) . The PFPMA block allows for self-assembly into nanoparticles in polar aprotic solvents (such as DMSO) followed by 1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo [4,5-c] quinolin-4-amine (IMDQ) ligation and cross-linking of the PFP esters with bisamines (24) without facing competing hydrolysis reactions that would occur in aqueous medium (25) . Furthermore, remaining pentafluorophenyl (PFP) esters can be converted into hydrophilic moieties to yield fully hydrated
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The newest generation of small-molecule vaccine adjuvants aims at triggering specific receptors expressed by dendritic cells, the working horses of our immune system. Unfortunately, owing to their small size, upon administration these molecules rapidly enter systemic circulation and cause systemic inflammation. We report on a nanotechnology-based solution for this issue by covalent ligation of a potent immunostimulatory small molecule to hydrogel nanoparticles. This approach allows for lymph node-restricted immune activation and avoids systemic dissemination. Importantly, relative to soluble immunostimulatory compound, nanoparticle ligation yields increased immune activation in the draining lymph nodes and results in strongly increased antibody titers and T-cell responses against an admixed vaccine antigen. nanogels after transfer to aqueous medium. Fig. 1 schematically represents the supramolecular design and chemical synthesis route that is elaborated on in this work.
Results and Discussion
Reversible addition-fragmentation chain transfer (RAFT) block polymerization of mTEGMA and PFPMA using 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid as chain transfer agent followed by dithiobenzoate end-group removal with an excess of azobisisobutyronitrile (SI Appendix, Scheme S1) yielded well-defined block copolymers with a number average molar mass (M n ) of 15.3 kDa and a dispersity (Ð) of 1.19. Detailed size-exclusion chromatography and 1 H, 13 C, and 19 F NMR analysis are provided in Fig. 2A and SI Appendix, Figs. S1-S6. Self-assembly of the block copolymers in DMSO yielded nanoparticles with a mean size of around 50 nm as measured by dynamic light scattering (DLS) (Fig. 2B and SI Appendix, Fig. S12 ). Subsequently, the TLR7/8 agonist IMDQ (26) was covalently ligated to the core of the nanoparticles through amide bond formation between the primary amine of IMDQ and the activated PFP esters in the nanoparticle core. Core cross-linking was performed by addition of the bis-amino-ketal 2,2-bis(aminoethoxy)propane, which installs pH-sensitive ketal moieties that render the cross-links susceptible to acid hydrolysis (25, 27) . Subsequently, the remaining unreacted PFP esters were converted to hydrophilic repeating units by addition of excess 2-aminoethanol. The latter in combination with the degradable cross-linker affords terminal degradation of the nanogels into fully soluble polymers composed of N-(2-hydroxyethyl)methacrylamide (HEMAm) units (SI Appendix, Fig. S14 ) that can be excreted from the body, thus avoiding longterm accumulation. As controls, non-cross-linked poly(mTEGMAb-HEMAm) polymers were prepared by omitting the 2,2-bis(aminoethoxy)propane cross-linker. Fluorescently labeled batches were prepared by adding the primary amine-bearing fluorescent dye AlexaFluor488-cadaverine (AF488) or tetramethylrhodamine cadaverine (TMR) before IMDQ ligation and cross-linking. Finally, transfer to aqueous medium was performed via dialysis, leading to fully hydrated nanogels. To confer nanogel stability against acid hydrolysis of the ketal cross-links, dialysis was performed in 0.015 M ammonia, which was then removed by lyophilization to yield nanogels as an easy-to-handle dry powder.
DLS data of the nanogels after redispersion in aqueous medium are shown in Fig. 2B and clearly indicate the formation of nanogels with similar size around 50 nm as measured in DMSO before transformation of the PFP esters (SI Appendix, Fig. S12 ). Stability of the cross-linked nanogels in response to different pH values was assessed by DLS incubating the nanogels in PBS (pH 7.4) and acetate buffer (pH 5), respectively. Fig. 2C and SI Appendix, Fig. S13 demonstrate that the nanogels readily swell in response to acidic medium and fully degrade afterward, whereas a much slower swelling is observed at physiological pH. These observations are a distinct advantage of the system, showing that the nanogels exhibit accelerated degradation in response to endo/ lysosomal pH, whereas also at physiological pH-although on a much longer time scale-degradation occurs. This feature could prevent long-term accumulation in the body of particles that did not end up in acidic milieu. Ligation of IMDQ could be monitored by 19 F NMR (SI Appendix, Fig. S7 ) and quantified via UV-visible spectroscopy (SI Appendix, Figs. S16, S17, and S19). Diffusionordered 1 H NMR spectroscopy (DOSY) as well as HPLC analyses confirmed successful ligation of IMDQ to the polymer backbone without any detectable signal of freely soluble IMDQ after the dialysis step (SI Appendix, Figs. S8-S11). Note that these experiments were performed on non-cross-linked samples to allow proper measurement. Thereby, spontaneous self-assembly was found for soluble polymers ligated to IMDQ. By contrast, IMDQ ligation had no influence on the nanogels' size and stability, as measured by DLS (SI Appendix, Fig. S15 ).
Next, we aimed to determine to what extent the IMDQ-ligated nanogels could activate bone marrow-derived dendritic cells (BMDCs) in vitro. DCs represent the most potent antigen-presenting cells and, thus, constitute the primary target of any adjuvant. Because TLR7/8 is localized on the endosomal membrane of DCs, nanogels must be internalized by DCs in order for IMDQ to reach its target receptor. To address internalization, we pulsed DCs with fluorescently labeled nanogels and soluble (non-cross-linked) polymer (for characterization see SI Appendix, Fig. S18 ) followed by flow cytometry (FACS) analysis and confocal microscopy. FACS analysis revealed a more profound association of DCs with nanogels compared with soluble polymer (Fig. 3A and SI Appendix, Fig. S20 ), a feature that can be attributed to the known preference of DCs to ingest particulate material (28) . Furthermore, the absence of cellular association upon incubation at 4°C indicates an energy-dependent uptake mechanism. Confocal microscopy indeed confirmed that both nanogels and soluble polymer were internalized by DCs at 37°C and were not merely attached to the cell surface (Fig. 3B) .
In a subsequent series of experiments, we set out to determine whether nanogel-ligated and non-cross-linked polymer-ligated IMDQ was still capable of activating its receptor in vitro. For this purpose, we pulsed mouse BM-DCs with either soluble IMDQ, polymer-ligated IMDQ, or nanogel-ligated IMDQ. Control samples were left untreated or pulsed with the polymer or nanogels without IMDQ. The extent of DC activation was quantified by flow cytometric (FACS) measurement of the surface expression of MHC class II (MHCII) and the costimulatory molecule CD80 ( these are inherently nonimmunogenic, at least under the experimental conditions used in these experiments. Second, polymer-and nanogel-ligated IMDQ was still capable of activating DCs, albeit to a lesser extent than the equivalent amount of soluble IMDQ at low doses. These results are in analogy with previous findings by us (26) , reporting that covalent modification of the primary amine of IMDQ with small molecules induced a reduction of its capacity to stimulate TRL7/8. Nevertheless, in our setting, macromolecular modification of IMDQ still provides access to its receptor and allows potent DC activation.
We then assessed to what extent nanogel-mediated delivery of IMDQ focuses innate immune activation to the site of injection and its DLN, a feature closely linked to adjuvant potency and minimized toxicity. To this end, we used IFN-β reporter mice in which a firefly luciferase encoding sequence had been placed under the control of the IFN-β promoter (29) . TLR7/8 agonists are indeed very potent inducers of type I IFN (including IFN-β), which are required for the adjuvant properties of TLR7/8 agonists but are also a cause of severe inflammatory toxicity when induced systemically (3, 5) . Whole-body imaging in IFN-β reporter mice enables a precise, spatiotemporal analysis of IFN-β induction in vivo and can therefore prove a useful predictive marker in estimating not only tissue disposition of the adjuvant but also in assessing systemic exposure. As mentioned earlier, the non-cross-linked polymer was less internalized by DCs in vitro and yielded ill-defined aggregates (Fig. 2B and SI Appendix,  Fig. S15 ). Nanogels, however, were monodisperse in size and, importantly, exhibited higher internalization in antigen-presenting cells. Furthermore, the surface-exposed carboxylate groups in nanogels could lend themselves to further derivatization with multiple copies of peptide and protein antigens (30) . Therefore, we chose to evaluate nanogels, and not the non-cross-linked polymer in vivo.
Mouse experiments were conducted following the European guidelines for animal experimentation and approved by the local ethical committee for animal experiments of Ghent University, Ghent, Belgium. Mice were injected s.c. in the footpad with 10 μg of either IMDQ (soluble, unconjugated small-molecule) or an equivalent dose of nanogel-ligated IMDQ (according to UV-visible spectroscopy (SI Appendix, Figs. S16 and S17), followed by full-body luminescence imaging of the luciferase signal at 4, 8, and 24 h postinjection. As depicted in Fig. 4A1 and SI Appendix, Fig. S23 , soluble IMDQ rapidly induced a systemic IFN-β response that coincided with a profound expression of IFN-β in the neck and abdomen of the injected mice. This early systemic production of type I IFN is most likely the consequence of the rapid diffusion of the injected IMDQ from the footpad to the circulation. These data are, thus, in perfect agreement with the reported biodistribution of the IMDQ-like TLR7/8 agonist 852A in humans. A mere 30 min after its administration, s.c. injected 852A indeed has been reported to reach the same concentration in the serum as i.v. injected 852A, thereby provoking a rapid elevation of type I IFN in the blood (9) . In contrast to soluble IMDQ, nanogel-ligated IMDQ induced a luciferase signal largely confined to the footpad and the draining popliteal lymph node at 4 h postinjection.
Most strikingly, when we calculated the ratio of local (DLN and DLN + foot pad) luminescence to total body luminescence (Fig.  4A2) , we observed that at all times addressed the local luminescence signal constituted a much higher part of the total body luminescence in the case of IMDQ nanogels. Taken together, these data indicate that ligation of IMDQ to the nanogels prevents systemic distribution of IMDQ but instead restricts its action to the injection spot and its DLNs, which should result in a strongly improved therapeutic index.
To confirm that IMDQ nanogels focus the inflammatory response on the local DLN, we compared the acute cellular inflammatory infiltrate in the DLN of soluble IMDQ-and IMDQ nanogel-injected mice. Granulocytes and monocytes are the first innate immune cells recruited to sites of infection or inflammation, which depends on their adhesion and subsequent transmigration through inflamed endothelial vessels. As depicted in Fig. 4B1 , nanogels by themselves did not increase the total cellularity of the DLN, nor did they elevate granulocyte or monocyte numbers in the DLN. Soluble IMDQ induced a weak increase in cellularity at the local DLN, which was mainly characterized by granulocyte influx but did not induce substantial monocyte recruitment. IMDQ nanogels, in contrast, caused a twofold increase in total DLN cellularity and recruited vast numbers of monocytes to the DLN. It is known that production of type I IFN induces strong expression of the monocyte chemoattractant protein MCP-1 (31) . In the case of IMDQ nanogels, the locally confined release of type I IFN thus results in local production of chemokines that attract high numbers of monocytes to the DLN. In the case of soluble IMDQ, however, type I IFNs are produced more systemically and even at higher levels in distant sites such as the neck and abdomen, a phenomenon that probably diverts monocytes to these sites instead. Next, we addressed to what extent IMDQ ligation affects nanogel uptake by immune cells in the DLN. To this end, AF488-labeled (SI Appendix, Fig. S19 ) nanogels were injected in the footpad followed by analysis of nanogel uptake by immune cells in the DLN through FACS (Fig. 4B2 ) and confocal imaging on tissue sections (Fig. 4C1  and SI Appendix, Fig. S24 ). Ligation of IMDQ to the nanogels resulted in a dramatic increase in the numbers of immune cells that became nanogel-positive. Nanogel-positive B cells were increased over 10-fold, nanogel-positive DCs over fivefold, nanogel-positive macrophages almost threefold, and nanogel-positive Ly6C hi monocytes showed an impressive 26-fold increase. In addition, the amount of nanogels taken up on a cell-per-cell basis was strongly enhanced by ligation of IMDQ. Macrophages, the immune system's most potent phagocytic cells, showed the highest uptake of IMDQ nanogels, followed by DCs, monocytes, and B cells. Ligation of IMDQ to the nanogels caused lymph node macrophages to ingest almost five times more nanogels compared with nanogels without IMDQ. Similarly, B cells and DCs, respectively, took up five and three times more IMDQ nanogels than nanogels without IMDQ. Although we observed a dramatic increase in the numbers of Ly6C hi monocytes that became nanogel-positive after IMDQ coupling to the nanogels, the amount of nanogels per monocyte was not significantly affected.
As can be appreciated from the confocal images in Fig. 4C1 and SI Appendix, Fig. S24 , injection of IMDQ-ligated nanogels caused a significant enlargement of the DLN compared with blank nanogels. To obtain a detailed view on the intranodal distribution of the nanogels, lymph node tissue sections were stained for B220 (B cells), CD3 (T cells), and CD11c (DCs). The vast majority of the injected nanogels localized to the subcapsular and medullary sinuses of the lymph node, a distribution typically observed when nanoparticles reach the lymph nodes by passive flow along the lymphatics. Indeed, particles with a size range between 10-200 nm enter lymphatic vessels by direct diffusion through lymphatic endothelial cell junctions and thus can reach the DLNs without prior cellular uptake (22) . Nevertheless, a minor part of such small particles will reach DLNs after uptake by tissue DCs that subsequently enter the lymphatics. Bigger particles, in contrast, exclusively rely on uptake by tissue DCs to enter the lymphatics and to reach the DLN. Such large particles are excluded from the subcapsular sinus and predominantly localize to the lymph node paracortex where DCs and T cells reside (32) . To confirm that passive drainage is indeed the major route of lymph node entry for the generated nanogels, we compared nanogel presence between the DLN of WT and CCR7 −/− mice. CCR7 is the chemokine receptor required for the migration of interstitial DCs from the peripheral tissue to the lymph nodes (33) . CCR7 −/− mice consequently lack these migratory DC populations in their lymph nodes-which do, however, still contain a population of lymph node resident DCs-and thus are highly defective in active transport of particles to the DLN. Confocal imaging of sections of the DLN of nanogel-injected revealed no significant differences in nanogel presence in the DLN of WT and CCR7 −/− mice ( Fig. 4C1 and SI Appendix, Fig. S25 ). These confocal data were confirmed by flow cytometry, because no significant differences were observed in the percentages of nanogel-positive B cells or nanogel-positive monocytes between WT and CCR7 −/− mice. Similarly, no significant differences were observed between the percentages of nanogel-positive monocytes, DCs, and B cells after injection of nanogels without IMDQ (Fig. 4C2) . Injection of IMDQ-ligated nanogels, in contrast, resulted in a slightly, but significantly, lower percentage of nanogel-positive DCs in CCR7 −/− mice. Such reduced percentage of nanogel-positive DCs in the absence of the migratory DC population suggests that active transport of nanogels by DCs becomes more substantial upon injection of IMDQ-ligated nanogels, a feature in perfect accordance with the described increased lymph node migration of tissue DCs in response to TLR activation (33) .
Finally, we aimed to address the functional impact of this localized IMDQ activity on the adaptive immune response against an admixed antigen. To this end, we coinjected soluble or nanogel-ligated IMDQ with the Mycobacterium tuberculosis antigen PPE44 (34) . As controls, mice were injected with PPE44 without adjuvant or with PPE44 admixed with nanogels without IMDQ. After 2 wk a booster immunization was performed and then 2 wk later we analyzed the vaccine-elicited PPE44-specific T-cell response by Enzyme-Linked ImmunoSpot (ELISPOT) assay and quantified the serum antibody titers. As can be appreciated from Fig. 4D , nanogel-ligated IMDQ was far more potent at eliciting IFN-γ secreting CD4 and CD8 T cells compared with soluble IMDQ. Soluble IMDQ did not significantly increase IFN-γ secretion in response to PPE44 immunization. When addressing serum antibody responses (Fig. 4E) we observed little effect of adding an adjuvant to PPE44 in terms of IgG1 titers. IgG2c antibody titers, however-which are strongly associated with Th1 skewed immune responses in C57BL/6 mice-were ∼100-fold elevated by coadministration of IMDQ nanogels compared with PPE44 alone or to nanogels without IMDQ. Crucially, IMDQ nanogels also induced 10-fold higher levels of IgG2c compared with soluble IMDQ, further stressing the tremendous importance of locally restricting IMDQ action for optimal priming of adaptive immune responses against codelivered protein antigens.
Conclusions
In summary, we have demonstrated an elegant route for covalent ligation of a small-molecule imidazoquinoline-based TLR7/ 8 agonist to well-defined pH-degradable polymeric hydrogel nanoparticles (i.e., nanogels). IMDQ nanogels combine the efficient triggering of TLR7/8 with focusing immune activation to the local injection site and its DLN. Spatially constrained immune activation is of vital importance because it limits the inflammatory toxicity associated with the use of soluble TLR agonists and thus should enable one to increase the dose and to obtain improved therapeutic efficacy. At the same time, focusing innate activation to the DLN has been demonstrated to augment the ensuing T-and B-cell response by several orders of magnitude upon coadministration of antigens (35, 36) . Indeed, nanogel-mediated delivery of IMDQ was more potent at inducing T-cell responses and antibody responses against admixed antigen compared with soluble IMDQ. Studies focusing on the covalent ligation of selected peptides and antigens to the nanogels could further unveil the potential of these IMDQ nanogels as adjuvants for vaccination. In addition, we also believe that intratumoral administration of immune-stimulatory nanogels may have the potential to improve the therapeutic benefit of locally applied imidazoquinolines in the context of anticancer immunotherapy.
